Unichem Laboratories Limited

NSE UNICHEMLAB.NS

Unichem Laboratories Limited EBIT for the year ending March 31, 2024: USD -4.68 M

Unichem Laboratories Limited EBIT is USD -4.68 M for the year ending March 31, 2024, a 76.00% change year over year. EBIT means earnings before interest and taxes, it is calculated as operating income plus non-operating income.

Unichem Laboratories Limited EBIT for the year ending March 31, 2023 was USD -19.48 M, a -646.77% change year over year.
Unichem Laboratories Limited EBIT for the year ending March 31, 2022 was USD 3.56 M, a -54.13% change year over year.
Unichem Laboratories Limited EBIT for the year ending March 31, 2021 was USD 7.77 M, a 242.15% change year over year.
Unichem Laboratories Limited EBIT for the year ending March 31, 2020 was USD -5.46 M, a 27.60% change year over year.

Key data

Date	EBIT	EBITDA	Net Income	EPS (Diluted)

NSE: UNICHEMLAB.NS

Unichem Laboratories Limited

CEO	Mr. Scott B. Delaney
IPO Date	July 1, 2002
Location	India
Headquarters	Unichem Bhavan
Employees	2,875
Sector	Health Care
Industries Pharmaceuticals

Description

Unichem Laboratories Limited, a pharmaceutical company, manufactures and sells pharmaceutical products worldwide. It offers formulation products that address various therapeutic areas, such as gastroenterology, cardiology, diabetology, psychiatry, neurology, anti-bacterial, anti-infective, and pain management; and active pharmaceutical ingredients, as well as contract manufacturing services. The company was founded in 1944 and is headquartered in Mumbai, India.

Key trends

Past 5 years